<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28320">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738047</url>
  </required_header>
  <id_info>
    <org_study_id>10202016</org_study_id>
    <nct_id>NCT02738047</nct_id>
  </id_info>
  <brief_title>Reduction of Adverse Drug Events and Readmissions</brief_title>
  <acronym>RADAR-PGX</acronym>
  <official_title>Pharmacogenomic Test Assessment for Medication Management in the Advancement of Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MD Global, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MD Global, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmocogenomic test assessment in the medication regimen and disease management for
      patients under drugs known with genetic variation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmocogenomic. A multicenter, observational study to evaluate the use of a Pharmocogenomic
      test assessment in the medication regimen and disease management for patients under drugs
      known to be influenced by genetic variation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>120 Days</target_duration>
  <primary_outcome>
    <measure>Radar, Pharmocogenomic</measure>
    <time_frame>The period of enrollment is anticipated to be 36 months with a 120- day follow-up period, for total study duration of approximately 40 months from first patient enrolled to completion of follow-up on the last patient in.</time_frame>
    <description>The primary endpoint of the study is the binary occurrence of meaningful change in drug regimen, defined in each patient when:
A genotype known to affect a drug the patient is taking is identified, *and*
The patient's treating physician makes at least one target drug regimen change, dose, substitution, or discontinuation.
Change in drug dose, substitution, or discontinuation among patients with an identified genotype known to affect a drug the patient is taking as directed. This will be assessed by a quantitative survey.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">280000</enrollment>
  <condition>Pharmacogenomic Testing for Medication Management</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are under treatment with several drugs with any of the sequences of
        biochemical reactions, catalyzed by enzymes, known to be influenced by genetic variation
        in a patient population.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

        Patients may be included in the Study if they meet all of the following inclusion
        criteria:

          1. Male or female patients of 25 years of age or older who are able to give their
             written Informed Consent to participate in a Clinical Study based on voluntary
             agreement with a thorough explanation of the patient's participation will be provided
             to them.

          2. Patient underwent PGx testing for alleles appropriate to the target drugs within the
             prior 120 days (&quot;index PGx test assessment&quot;);

          3. Patient was receiving at least one medication known to be associated with allelic
             variation at the time of the (&quot;index PGx test assessment&quot;), including over-the-
             counter medications;

          4. Patient has a history of at least one TDAE over the 24-month period preceding the PGx
             test assessment, or has experienced inadequate efficacy from a target drug.

        EXCLUSION CRITERIA

        Patients will be excluded from the Study if any of the following criteria apply:

          1. Patient is currently hospitalized;

          2. Patient's medical and medication history is unavailable over the 120-day period
             preceding the PGx test assessment;

          3. Patient is unable to provide an accurate history due to mental Incapacity;

          4. Patient is known to have undergone prior PGx testing for genes specific to the target
             drug(s), exclusive of the PGx test relating to this Study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis Rosenfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiac Services Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Cohen, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Research for Professionals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Brewer</last_name>
    <phone>239-908-0413</phone>
    <email>Dave.B@Radar-PGxStudy.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana M Messir</last_name>
    <phone>239-908-0412</phone>
    <email>Diana.M@Radar-PGxStudy.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AKDHC Medical Research Services</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>N. Roxanna Neyra, M.D.</last_name>
      <phone>602-351-3041</phone>
    </contact>
    <investigator>
      <last_name>N. Roxanna Neyra, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEA Baptist Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wallace S Hoke, M.D.</last_name>
      <phone>870-934-5755</phone>
    </contact>
    <investigator>
      <last_name>Wallace S Hoke, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elk Grove Clinical Research</name>
      <address>
        <city>Elk Grove</city>
        <state>California</state>
        <zip>95757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dwight Bass, M.D.</last_name>
      <phone>916-513-7027</phone>
    </contact>
    <investigator>
      <last_name>Dwight Bass, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesa Behavioral Clinic</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Sammons, M.D., Phd</last_name>
      <phone>970-242-6135</phone>
    </contact>
    <investigator>
      <last_name>Robert Sammons, M.D., Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc C Gittleman, M.D.</last_name>
      <phone>305-931-8080</phone>
    </contact>
    <investigator>
      <last_name>Marc C Gittleman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advance Medical Research Service Corp.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Blas E. Prieto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ITB Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33182</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivianne Zerquera</last_name>
      <phone>305-274-4351</phone>
      <email>vzerquera.itb@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gregory Alfred, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NeuroMedical Research Institute</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassi Hiers</last_name>
      <phone>850-215-7093</phone>
    </contact>
    <contact_backup>
      <last_name>Beth Golden</last_name>
      <phone>8502157093</phone>
    </contact_backup>
    <investigator>
      <last_name>George Barrio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverley Jenkins</last_name>
      <phone>770-507-8344</phone>
    </contact>
    <investigator>
      <last_name>Phillip Nowlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florea Buckeye Health &amp; Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Florea, M.D.</last_name>
      <phone>614-850-7450</phone>
    </contact>
    <investigator>
      <last_name>Robert Florea, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palmetto Research Center, LLC</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald H Littlefield, M.D.</last_name>
      <phone>864-582-6202</phone>
    </contact>
    <investigator>
      <last_name>Ronald H Littlefield, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 9, 2017</lastchanged_date>
  <firstreceived_date>March 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
